2015
Authors: Turkova A, Giacomet V, Goetghebuer T, et al.
Published in: J Virus Erad. 2015;1(3):179-184
Objectives To describe use of treatment for chronic hepatitis C virus (HCV) infection in HIV/HCV co-infected children and young people living in Europe and to evaluate treatment outcomes.
Methods HCV treatment data on children and young people aged <25 years with HIV/HCV co-infection were collected in a cohort collaboration of 11 European paediatric HIV cohorts.
2015
Authors: Paediatric European Network for Treatment of AIDS (PENTA).
Published in: AIDS 2015. 29(18):2447-2457
Objective To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in children.
Design International, multicentre, phase II/III, randomized, open-label, noninferiority trial (KONCERT/PENTA18/ANRS150).
Setting Clinical centres participating in the PENTA,
2015
Authors:
Published in: AIDS 2015, 29:2447-2457
Objective To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in children.
Design International, multicentre, phase II/III, randomized, open-label, noninferiority trial (KONCERT/PENTA18/ANRS150).
Setting Clinical centres participating in the PENTA, HIV-NAT and PHPT networks.
Participants Children/adolescents with HIV-1 RNA viral load less than 50 copies/ml for at least 24 weeks on lopinavir/ritonavir-containing antiretroviral therapy.
2015
Authors: Karina M. Butler on behalf of the BREATHER trial team
Published in: CROI 2015, Seattle, USA, Feb 23 -26 2015.
Abstract For HIV-1 infected young people (YP) facing lifelong ART, short cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity and better adherence, as well as cost savings.
2015
Authors: Freguja R, De Rossi A, Paulson H, Klein N, Del Bianco P, Compagnucci A, Saidi Y, Giaquinto C, Harper L, Gibb D, on behalf of the PENTA Steering Committee
Published in: CROI 2015, Seattle, USA, Feb 23 -26 2015. Poster presentation abstract 919
2015
Authors: Colbers A, Molto J, Ivanovic J, et al. PANNA Network
Published in: J Antimicrob Chemother. 2015; 70(2):534-542
Objectives To describe the pharmacokinetics of darunavir in pregnant HIV-infected women in the third trimester and post-partum.
Patients and Methods This was a non-randomized, open-label, multicentre, Phase IV study in HIV-infected pregnant women recruited from HIV treatment centres in Europe.
2015
Authors: Harrison L, Melvin A, Fiscus S, et al; PENPACT-1 (PENTA 9PACTG 390) Study Team.
Published in: J Acquir Immune Defic Syndr. 2015;70(1):42-53
Background The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold.
2015
Authors: Colbers A, Hawkins D, HidalgoTenorio C, et al.
Published in: Antivir Ther. 2015; 20(1):57-64
Background We studied the effect of pregnancy on atazanavir pharmacokinetics in the presence and absence of tenofovir.
Methods This was a non-randomized, open-label, multicentre Phase IV study in HIV-infected pregnant women recruited from European HIV treatment centres.
2014
Authors: Colbers A, Gingelmaier A, van der Ende M, Rijnders, B, Burger D.
Published in: AIDS 2014;28(2): 288-290
2014
Authors: Bailey H, Townsend C, Semenenko I, Malyuta R, Cortina-Borja, Thorne C; for the Ukraine European Collaborative Study in EuroCoord
Published in: BMC Public Health. 2014; 24(14):993
Background Poor adherence to antiretroviral therapy (ART) is associated with HIV disease progression and, during
pregnancy, increased mother-to-child transmission risk. In Ukraine, access to combination ART is expanding but data
on adherence are scarce.
2014
Authors: Colbers A, Hawkins D, Hidalgo-Tenorio C, van der Ende M, Kabeya K, Gingelmaier A, Weizsäcker K, Lambert J, Rockstroh J, Burger D; on behalf of the PANNA network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, March 3rd-6th 2014, Boston. P_892
2014
Authors: Blonk M, Colbers A, Hidalgo-Tenorio C, Weizsäcker K, Moltó J, Hawkins D, van der Ende M, Gingelmaier A, Taylor G, Burger D; on behalf of the PANNA network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, March 3rd-6th 2014, Boston. P_890
2014
Authors: Colbers A, Moltó J, Ivanovic J, Hawkins D, Sadiq T, Kabeya K, Gingelmaier A, Weizsäcker K, Taylor G, Burger D; on behalf of the PANNA network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, March 3rd-6th 2014, Boston. P_887
2014
Authors: Turkova A; for the European Paediatric HIV/HCV Co-infection Study Group in the European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord.
Published in: 20th International AIDS Conference (AIDS 2014), July 20th-25th 2014, Melbourne, Australia.
2014
Authors: Bagkeris E, Bailey H, Malyuta R, Volokha A, Thorne C
Published in: 6th International Workshop on HIV Pediatrics, July 18th-19th 2014, Melbourne, Australia.
2014
Authors: Yin D., Warshaw M., Miller W., Castro H., Fiscus S., Harper L., Harrison L., Klein N., Lewis J., Melvin A., Tudor-Williams G., McKinney R.
Published in: Pediatrics, 2014;134(4):e1104-16
2014
Authors: Judd A, Duong T, Galli L, et al; on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration study group in EuroCoord.
Published in: Pharmacoepidemiol Drug Saf. 2014;23(3):321-5
Purpose Fosamprenavir, combined with low-dose ritonavir (FPV/r), is indicated for treatment of HIV-infected children aged ≥6 years in Europe. Our purpose was to assess the safety of licensed use of FPV/r in HIV-infected children reported to six cohorts in the European Pregnancy and Paediatric HIV Cohort Collaboration.
2014
Authors: Bastiaans DE, Forcat S, Lyall H, et al.
Published in: Pediatr Infect Dis J. 2014;33(3):301-305
Background Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) as part of combination antiretroviral therapy. Dosing is based on body weight bands or body surface area under FDA approval and only body surface area by the EMA.
2014
Authors: Harrison L, Gibb DM, Fiscus S, Saïdi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, Melvin A, Tudor-Williams G and the PENPACT 1 (PENTA 9/PACTG 390) Study Team.
Published in: CROI 2014, 3-6 March 2014, Boston. Poster 898.
2014
Authors: Judd A, Collins J, Lodi S, Olson A, Pantazis N, Gibb DM; on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord
Published in: 18th International Workshop on HIV Observational Databases, March 27th-29th 2014, Sitges, Spain.
2014
Authors: Judd A, Childs T, Collins J, Dodonov K, Galli L, Goetghebuer T, Konigs C, Noguera-Julian A, Rojo Conejo P, Naver L, Tookey P, Giaquinto C; on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord.
Published in: 18th International Workshop on HIV Observational Databases, March 27th-29th 2014, Sitges, Spain.
2014
Authors: Bailey H, Thorne C, Giaquinto C, Tookey P; for the UK and Ireland National Study of HIV in Pregnancy and Childhood and the European Collaborative Study in EuroCoord.
Published in: 18th International Workshop on HIV Observational Databases, March 27th-29th 2014, Sitges, Spain.
2013
Authors: Klein N, Sefe D, Mosconi I, et al; on Behalf of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team
Published in: PLoS One. 2013;8(10):e76582.
Design This was an immunological and virological sub-study of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial,
2013
Authors: Colbers A, Brookie B, Wang J, Stek A, Hidalgo-Tenorio C, Hawkins D, Taylor G, Capparelli E, Burger D, Mirochnick M; on behalf of the PANNA network
Published: 20th Conference on Retroviruses and Opportunistic Infections, March 3rd-6th 2013, Atlanta. P_931
2013
Authors: Turkova A, Thorne C, Galli L, Goetghebuer T, de Martino M, Oprea C, Ramos Amador JT, Giaquinto C; for the European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord.
Published in: 7th International AIDS Society Conference (IAS 2013), Kuala Lumpur, 30th June – 3rd July 2013
2013
Authors: Thorne C, Bailey H, Semenenko I, Tereschenko R, Adeyanova I, Kulakovskaya E, Ostrovskaya L, Malyuta R
Published in: 7th International AIDS Society Conference (IAS 2013), Kuala Lumpur, 30th June – 3rd July 2013
2013
Authors: D Bastiaans, S Forcat, H Lyall, T Cressey, S Chalermpantmetagul, Y Saïdi, C Koenigs, D Nayagam, A Compagnucci, S Montero, L Harper, C Giaquinto, E Colbers, D Burger.
Published in: 31st Annual Meeting of the ESPID- May 28 – June 1, 2013, Milan: Poster discussion Abstract A-534-0018-00429.
2013
Authors: Aebi-Popp K, Mulcahy F, Glass T, Rudin C, Martinez de Tejada B, Bertisch B, Grawe C, Rickenbach M, Scheibner K, Hösli I and Thorne C for the European Collaborative Study in EuroCoord and the Swiss Mother & Child HIV Cohort Study.
Published in: 5th International HIV Pediatrics Workshop, Kuala Lumpur, 28-29 June 2013.
2013
Authors: Aebi-Popp K, Mulcahy F, Glass TR, et al.; for the European Collaborative Study in EuroCoord and the Swiss Mother & Child HIV Cohort Study.
Published in: J Acquir Immune Defic Syndr. 2013;64(1):58-65
Introduction Most national guidelines for the prevention of mother-to-child transmission of HIV in Europe updated between 2001 and 2010 recommend vaginal deliveries for women with undetectable or very low viral load (VL).
2013
Authors: Bailey H, Townsend CL, Cortina-Borja M, Thorne C; for the European Collaborative Study in EuroCoord.
Published in: AIDS 2013; 27:2312-2315
Abstract Among 396 HIV-infected women conceiving on combination antiretroviral therapy and enrolled in the European Collaborative Study in 2000–2011, the proportion with virological failure (>200 copies/ml after ≥24 weeks of treatment) declined substantially from 34% in 2000–2001 to 3% in 2010–2011.
2013
Authors: Chiappini E, Galli L, Giaquinto C, et al. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.
Published in: AIDS 2013; 27(6): 991-1000
Objectives To evaluate use of combination neonatal prophylaxis (CNP) in infants at high risk for mother-to-child transmission(MTCT) of HIV in Europe and investigate whether CNP is more effective in preventing MTCT than single drug neonatal prophylaxis (SNP).
2013
Authors: Colbers AP, Hawkins DA, Gingelmaier A, et al.
Published in: Aids. 2013; 27(5):739-748.
Objective To describe the pharmacokinetics of tenofovir and emtricitabine in the third trimester of pregnant HIV-infected women and at postpartum.
Design A nonrandomized, open-label, multicentre phase IV study in HIV-infected pregnant women recruited from HIV treatment centres in Europe.
2013
Authors: Bunupuradah T, Duong T, Compagnucci A, et al; on behalf of the PENTA 11 Extension Study Group
Published in: AIDS. 2013;27(4):579-89
Background Excess risks for death/opportunistic disease in adults randomized to CD4-driven planned treatment interruption (PTI) in the Strategies for Management of Antiretroviral Therapy (SMART) trial remained after antiretroviral therapy (ART) re-initiation. Risks for childrenfollowing PTI were evaluated in long-term follow-up of children in the PENTA 11 trial.
2013
Authors: Harrison L, Ananworanich J, Hamadache D, et al; on Behalf of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team
Published in: AIDS Behav. 2013;17(1):193-202.
Abstract There have been no paediatric randomised trials describing the effect of planned treatment interruptions (PTIs) of antiretroviral therapy (ART) on adherence, or evaluating acceptability of such a strategy.
2012
Authors: Colbers A, Taylor G, Moltó J, Ivanovic J, Wyen C, Schwarze-Zander C, Weizsäcker K, Gingelmaier A, Hawkins D, Sadiq T, Kabamba K, Burger D; on behalf of the PANNA network
Published: 13th International Workshop on Clinical Pharmacology of HIV Therapy, 2012 April 16th-18th, Barcelona
2012
Authors: Colbers A, Moltó J, Ivanovic J, Hidalgo-Tenori C, Weizsäcker K, van der Ende I, Hawkins D, Taylor G, Sadiq T, Burger D; on behalf of the PANNA network
Published: 19th Conference on Retroviruses and Opportunistic Infections, March 5th-8th 2012, Seattle. P_103
2012
Authors: European Collaborative Study in Eurocord
Published in: Antivir Ther, 2011,16: 859-903.
Background: Although mother-to-child transmission (MTCT) rates are at an all-time low in Western Europe, potentially preventable transmissions continue to occur. Duration of antenatal combination antiretroviral therapy (ART) is strongly associated with MTCT risk.
Methods: Data on pregnant HIV-infected women enrolled in the Western and Central European sites of the European Collaborative Study between January 2000 and July 2009 were analysed.
2012
Authors: Bastiaans DET, Forcat S, Lyall HEG, Cressey TR, Chalermpantmetagul S, Saïdi Y, Noguera T, Fortuny C, Compagnucci A, Bleier J, Giaquinto C, Colbers EP, Burger DM.
Published in: 4th International Workshop on HIV pediatrics 2012. July 20-21, 2012. L’Enfant Plaza Hotel, Washington DC, USA. 4th International Workshop on HIV pediatrics. July 20-21, 2012. L’Enfant Plaza Hotel, Washington DC, USA.
2012
Authors: Ramos J., Melvin D, Medin G, Compagnucci A, Bleier J, Boscolo V, Barclay L, Ory S, Giaquinto C, Gibb D. on behalf of the PENTA Steering Committee.
Published in: 19th Conference on Retroviruses and Opportunistic Infections, San Francisco, 5-8 March 2012, Poster
2012
Authors: Antinori A., Marcotullio S., Ammassari A., Andreoni M., Angarano G., Armignacco O., Carosi G., Cinque P., d’Arminio Monforte A., Di Perri G., Ensoli B., Florida M., Galli M., Mastroianni C., Matteelli A., Mazzotta F., Moroni M., Pal G., Puoti M., Puro V., Rizzardini G., Sagnelli E., Vella S., Vullo V., Lazzarin A., Italian HIV Guidelines Working Group (Giaquinto C. member of Study Group)
Published in: New Microbiol 2012,
2012
Authors: Mbisa JL, Hue S, Buckton AJ, et al.
Published in: AIDS Res Hum Retroviruses. 2012;28(9):1161-1166
Abstract In the late 1980s an HIV-1 epidemic emerged in Romania that was dominated by subtype F1. The main route of infection is believed to be parenteral transmission in children. We sequenced partial pol coding regions of 70 subtype F1 samples from children and adolescents from the PENTA-EPPICC network of which 67 were from Romania.
2012
Authors: D Bastiaans, S. Forcat, H.E.G. Lyall, T.R. Cressey, S. Chalermpantmetagul, Y. Saïdi, H.J. Scherpbier, A. Warris, A. Compagnucci, C. Giaquinto, E.P. Colbers, D.M. Burger on behalf of PENTA KONCERT Study Group.
Published in: 6th Netherlands Conference on HIV Pathogenesis, Prevention and Treatment. November 27, 2012.
2012
Authors: Chiappini E., Galli L., Tovo P.A., Gabiano C., Lisi C., Giacomet V., Bernardi S., Esposito S., Rosso R., Giaquinto C ., Badolato R., Guarino A., Maccabruni A., Masi M., Cellini M., Salvini F., Di Bari C., Dedoni M., Dodi I., De Martino M for the Italian Register for HIV infection in children
Published in: Acta Paediatr, 2012, 101: 287-295
Background: Information on the use of new antiretroviral drugs in children in the real setting of clinical fields is largely unknown.
2012
Authors: Alam N., Cortina – Borja M., Goetghebuer T., et al. European Paediatr HIV & Lipodystrop (Giaquinto C. member of the Study Group)
Published in: JAIDS, 2012, 59: 314 – 32
Objectives: To estimate the prevalence of and identify risk factors for lipodystrophy syndrome (LS) and body fat abnormality in a population of HIV-infected children and adolescents.
2012
Authors: Goetghebuer T, Le Chenadec J, Haelterman E, et al.
Published in: Clinical Infectious Diseases 2012; 54(6): 878-881
Abstract The clinical benefit of antiretroviral therapy in infants is established. In this cohort collaboration, we compare immunological and virological response to treatment started before or after 3 months of age. Early initiation provides a better short-term response,
2011
Authors: Lewis J, Walker AS, Castro H, et al.
Published in: J Infect Dis. 2011;205(4):548-556
Background Effective therapies and reduced AIDS-related morbidity and mortality have shifted the focus in pediatric human immunodeficiency virus (HIV) from minimizing short-term disease progression to maintaining optimal long-term health. We describe the effects of children’s age and pre-antiretroviral therapy (ART) CD4 count on long-term CD4 T-cell reconstitution.
2011
Authors: The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.
Published in: AIDS 2011; 25(18): 2279-2287
Background Durable and tolerable first-line antiretroviral therapy (ART) regimens are needed for HIV-infected infants who may need life-long treatment. We investigated virological and immunological response to ART, and predictors of switching and interrupting treatment among infants starting ART in the European Pregnancy and Paediatric HIV Cohort Collaboration.
2011
Authors: Colbers A, Taylor G, Moltó J, Ivanovic J, Taylor G, Branco T, Wyen C, van der Ende I, Gomes da Silva H, Burger D; on behalf of the PANNA network
Published: 12th International Workshop on Clinical Pharmacology of HIV Therapy, 2011 April 13th-15th, Miami. P_18
2011
Authors: Compagnucci A. on behalf of the PENTA Steering Committee
Published in: 3rd HIV Paediatric Workshop Rome 15-16 July 2011.
2011
Authors: Wittkop L, Günthard HF, de Wolf F, et al. EuroCoord-CHAIN study group.
Published in: Lancet Infectious Diseases 2011; 11(5): 363-71
Background The effect of transmitted drug resistance (TDR) on first-line combination antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug regimens. We investigated the effect of TDR on outcome in the first year of cART within a large European collaboration.